Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Hanx Biopharmaceuticals has dosed the first subject in a trial of HX044, a bispecific antibody designed for advanced solid tumours.

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in post-surgery pain compared to placebo.

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of CC-42344 ...

According to GlobalData, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since 2004.

IMCA at the Israel Ministry of Health has renewed SciSparc’s trial of SCI-210 for treating paediatric patients with autism spectrum disorder.

Novartis is preparing to present the trial findings to regulatory bodies in 2025. Credit: Novartis AG. Novartis has reported positive topline outcomes from the Phase III STEER trial of an ...

Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501.